Abstract

Using a Burkitt's lymphoma (BL) cell model, the present inventors have shown that it is possible to suppress the synthesis of c-Myc by using specific compounds that bind to MDM2. The present inventors have shown that under low-cell proliferation conditions, MDM2 binds to the 5' untranslated region (UTR) of the c-Myc mRNA and suppresses its synthesis in a p53-independent manner, but 5 that this interaction does not take place under under medium/high cell proliferation conditions due to a conformational change in MDM2. The inventors have shown that under such conditions, it is possible to use specific MDM2-binding agents that induce an allosteric transition of MDM2 to promote its ability to interact with c-Myc mRNA, thereby suppressing its expression. The present invention therefore pertains to an MDM2-binding agent for use in the treatment of a proliferative disorder, 10 wherein said agent restores the c-Myc binding conformation of MDM2 and wherein said proliferative disorder is a p53-mutated disorder.

IPC Classes  ?

• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to an ophthalmic composition, comprising a nonionic oil-in-water emulsion with: • an aqueous phase Aq, • a lipid phase L, in the form of droplets dispersed in the aqueous phase, • an interface between said lipid phase L and said aqueous phase Aq, and • a particulate surface-active agent for stabilizing the emulsion, located at the interface between the lipid phase and the aqueous phase, said surface-active agent comprising or consisting of organic particles with an average size of less than or equal to 1 μm, said composition being free of non-particulate surfactant, and advantageously free of preservative. These compositions are useful as a medicament, in particular for administration by ocular instillation. The invention also relates to a method for preparing said compositions.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions

Abstract

This invention relates to recombinant lentiviral vectors, compositions thereof, the use of the vectors or the compositions thereof, kits of parts comprising said vectors or compositions thereof and a catalytically active Cas9 or Cpf1 protein, methods for modifying the genome of a hematopoietic stem/progenitor cell (HSPC), and the HSPC obtainable by such methods.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 38/42 - HaemoglobinsMyoglobins
• C12N 5/074 - Adult stem cells
• C12N 9/22 - Ribonucleases

Abstract

The invention relates to a medical device (2) for detecting the occurrence of a medical condition in a subject (4), the medical device including a processing unit configured to: - based on a position of a plurality of landmarks, each landmark being representative of a respective joint of the subject (4), compute a trajectory set associated with the subject (4), the trajectory set including a trajectory of at least one point of interest, each point of interest being a barycenter of a respective landmark set including at least two landmarks; determine whether the subject (4) exhibits a medical condition or not, based on the computed trajectory set.

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06T 7/20 - Analysis of motion
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/08 - Measuring devices for evaluating the respiratory organs
• A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
• A61B 5/113 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb occurring during breathing

Abstract

The present invention relates to a composition comprising bacteria of the strain L. casei SGC-K deposited at the National Collection of Cultures of Microorganisms in the Institut Pasteur, Mar. 8, 2021, under no. CNCM 1-5663. The invention also relates to the nutritional and therapeutic uses of said composition.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

Insults to vital organs have serious and even life-threatening consequences. Organ insults have different etiologies and typically include drugs, toxins and ischemic insults. Acyl-CoA binding protein (ACBP), also known as diazepam-binding inhibitor (DBI), is an extracellular feedback regulator of autophagy. Here, the inventors report that injection of a monoclonal antibody neutralizing ACBP/DBI (α-DBI) protects the murine liver against ischemia/reperfusion damage, acute intoxication by acetaminophen and concanavalin A, as well as against liver fibrosis induced by bile duct ligation or carbon tetrachloride. Of note, the results support the contention that α-DBI mediates broad organ-protective effects against multiple insults. Thus, the present invention relates to methods and pharmaceutical composition of protecting organs from injuries comprising neutralization of Acyl-CoA Binding Protein.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The invention relates to the detection of the risk for a patient with a congenital Long QT (LQT) condition for having a torsades-de-pointes event, and the mechanisms underlying such risk, in particular via the use of neural networks.

IPC Classes  ?

• A61B 5/346 - Analysis of electrocardiograms

Abstract

The present invention relates to methods for predicting response to an immunotherapeutic treatment in a patient with a cancer.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention concerns the modulation of the macrophage function. The inventors have discovered that this function can be modified by applying a sequence of repetitive magnetic stimulations having a frequency comprised between 2 Hz and 20 Hz. This opens the way to a non-invasive control of the macrophage and, thereby, of any use that implies the macrophage.

IPC Classes  ?

• C12N 5/0786 - MonocytesMacrophages
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
• A61P 31/04 - Antibacterial agents
• C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation

Abstract

Apparatus (1) for simulating a gynaecological examination, configured to simulate different configurations of cervical effacement, comprising:—a corolla (3) extending in a plane (P) perpendicular to an axis (X) and configured to simulate the feel of a vaginal wall, and—a member (5) configured to simulate a tactile sensation of a cervix, the corolla (3) extending radially on the outside of the member (5) with respect to the axis (X), the member (5) being mounted movably with respect to the corolla (3) along the axis (X), such that the member (5) is configured to move in translation along the axis (X) between:—a reference configuration, in which the member (5) extends entirely towards the outside of the apparatus (1) starting from the plane (P):—an effaced configuration, in which the member (5) extends entirely towards the inside of the apparatus (1) starting from the plane (P).

IPC Classes  ?

• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine

Abstract

The prediction of the tumor stage is very difficult and is notably problematic to carry out a proper follow-up of the treatment of the tumor. The Applicant has found a way to circumvent such problem by proposing a computer tool which is adapted to predict the tumor stage of a subject, based on original parameters; a volume of the tumor calculated based on images obtained by one modality, at least one parameter relative to the interaction between a chemical agent and the tumor, and t least one parameter relative to the presence of tumor vessels in a volume containing the tumor.

IPC Classes  ?

• G06T 7/00 - Image analysis

Abstract

Sarbecoviruses (lineage B of genus Betacoronavirus) have caused two major outbreaks during the past two decades: SARS-CoV in 2003, and SARS-CoV-2 from 2019. SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. Therefore, universal vaccines against this class of viruses are key to ending the current pandemic, but also for preventing additional emergent variations and future outbreaks of SARS-like viruses that are continuously found from nature reservoirs. Now, the inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain is conjugated or fused to a protein N polypeptide of SAR-CoV-2 and the light chain is fused to a RBD polypeptide. In particular, the inventors show that said antibody could elicit immune responses against Sarbecoviruses.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

This elbow orthosis comprises a first fitting, a second fitting and a mechanical stop arrangement (40) configured for limiting the angular movement of the second fitting with respect to the first fitting around a first rotation axis (A1). The mechanical stop arrangement (40) includes first and second plates (402, 404), each provided with a circular slot (4024, 4044) and a series of through holes (4028, 4048) spread on a circle centered on a central axis (A402, A404) of the circular, and a crank (408) equipped with a pin (409) engaged in the circular slots (4024, 4044). The first and second plates (402, 404) are aligned on a common central axis and their relative orientation around this common axis is set by aligning at least one through hole (4028) of the first plate with one through hole (4048) of the second plate. Some portions of the circular slots (4024, 4044) overlap, depending on the orientation of the first and second plates around the common axis. The extremities (4024A, 4024B, 4044A, 4044B) of the overlapping portions of the circular slots define the amplitude of the maximum angular movement of the second fitting with respect to the first fitting when it is driven by a worm-and-wheel transmission (22).

IPC Classes  ?

• A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces

Abstract

The present invention relates to a new and specific T-cell therapy strategy based on the use of memory stem T-cells (Tscm), in particular highly functional memory stem T-cells (Tscm) negatively selected on the basis of inhibitory receptor expression. This new cellular immunotherapy may be applied to PML patients but also to other infections or cancers for which the specific memory T cell responses are functionally impaired.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to a method for diagnosing or identifying a colorectal cancer in a subject, through the detection of the abnormal hypermethylation levels of specific genes in a biological sample of said subject. The inventors indeed identified DNA methylation biomarkers that, alone or in combination, can help diagnosing or following-up colorectal cancer patients. Further, it can be used for determining, and/or adapting a suitable therapeutic regimen for a subject diagnosed for colorectal cancer. The present invention also relates to kits comprising primers or probes to detect, diagnose, or identify hypermethylated genes.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present inventors have found that a molecule mimicking miR-27a-5p is capable of strongly modulating the inflammatory response in a well-known animal model of inflammatory bowel disease (IBD). Therefore they propose incorporating this mimic into a pharmaceutical composition for treating patients suffering from this disease. Advantageously, this mimic can be linked to a matrix, incorporated into particles, or conveyed by a vector.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to a compound selected from mepyramine, prodrugs thereof and pharmaceutically acceptable salts thereof, or a composition comprising such a compound, for use in the topical treatment and prevention of a disease affecting oral mucosa, such as oral mucositis or burning mouth syndrome.

IPC Classes  ?

• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/05 - Phenols
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to a device for obtaining a trained machine learning segmentation model for carotid segmentation using positron emission tomography (PET) images of a patient and to a device and a computer-implemented method for carotid segmentation of positron emission tomography (PET) frames previously acquired on a patient using the trained machine learning segmentation model (31) for carotid segmentation, wherein said segmentation model is configured to provide a segmentation mask of the at least one portion of interest of the carotid arteries.

IPC Classes  ?

• G06T 7/174 - SegmentationEdge detection involving the use of two or more images
• A61B 6/03 - Computed tomography [CT]
• G06T 7/11 - Region-based segmentation

Abstract

The present invention relates to a method for ex vivo measuring glomerular filtration rate (GFR) of a subject to whom a contrast agent has been administered, and to whom computed tomography (CT) or magnetic resonance imaging (MRI) including an excretory phase, an unenhanced phase, an arterial phase, and a nephrographic or a venous portal phase has been performed, said method comprising the step of calculating the clearance of the contrast agent from CT or MRI data using manual, automated or semi-automated segmentation software, thereby obtaining a measured GFR.

IPC Classes  ?

• A61B 5/20 - Measuring urological functions
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment

Abstract

The present invention relates to the treatment of inflammatory bowel diseases with a kynurenine aminotransferase, a living recombinant bacterium which has been genetically modified to express and secrete said kynurenine aminotransferase, and/or a product of said kynurenine aminotransferase which is xanthurenic acid, a derivative thereof, or any pharmaceutically acceptable salt or solvate thereof.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 35/74 - Bacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to a method for detecting a change in a patient's physiological condition with respect to a reference physiological condition. The method is based on a multimodal analysis that involves measurements of electroencephalography signals Si from the patient and at least one other physiological signal SN+1(N≥1) from the patient. Based on these measurements, the invention proposes calculating distances di(m) associated with the electroencephalography measurements and with the measurements of the other physiological signals and fusing these data, the data having previously undergone a certain number of mathematical processing operations. In the context of the invention, the fused data may be assigned a weighting coefficient chosen according to one or more a priori or a posteriori criteria.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/31 - Input circuits therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/369 - Electroencephalography [EEG]
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation

Abstract

Anaplastic large cell lymphoma (ALCL) is a rare and aggressive peripheral T-cell lymphoma affects lymph nodes and extra-nodal sites with characteristic skin lesions. Approximatively half of the tumors express the NPM1-ALK fusion from the translocation t(2;5)(p23;q32). In the present study, the inventors identify ROR2 as progressively up regulated thought tumorigenesis. Patient samples show a significantly high ROR2 expression (transcriptomic data) as well as a strong ROR2 protein expression (IHC) with some tumors displaying a clear membrane signal. ROR2 mRNA expression level is also positively correlated to NPM-ALK expression level in tumor cells and is not expressed in normal T cells. In addition, ROR2 protein level is significantly increased in resistant cells to the ALK inhibitor, crizotinib, used in clinical trials for children with refractory tumors. This result opens the road to ROR2 specific therapies: ROR2 inhibitors, monoclonal antibodies therapies or even ROR2 specific CAR cells, including for ALCL ALK(+) resistant tumors.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention relates to a balloon cuff (1) for a tracheal intubation device, the balloon cuff (1) being elastically deformable and extending between an inner surface (3) surrounding an axis (A) and an outer surface (5) surrounding the inner surface (3), the balloon cuff (1) comprising inner walls that define ducts (13, 15) that extend through the balloon cuff, the balloon cuff (1) being configured to go from a deflated state to an inflated state by injecting a fluid into the ducts (13, 15) such that the outer surface (5) moves away from the axis.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes

Abstract

The invention relates to the field of anesthesia and of monitoring of the patient's state during anesthesia, notably the blood perfusion of the brain, using data from the electroencephalogram of the patient.

IPC Classes  ?

• A61B 5/026 - Measuring blood flow
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves

Abstract

The present invention relates to a targeted chimeric construct, comprising i) an interleukin 2 (IL2) moiety and ii) a targeting moiety which binds to an oxidized protein or oxidized lipid. The targeting moiety is preferably an antibody or scFv binding specific oxidized proteins or oxidized lipids and targets the fusion protein to inflammatory tissues. The chimeric construct preferably further comprises a beta chain of the C4b-binding protein (C4BP), which is capable of forming a dimeric protein.

IPC Classes  ?

• C07K 14/55 - IL-2
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to tertiary amine compounds, containing an alkyne group or an azide group, in particular an alkyne group, including their pharmaceutically acceptable salts and solvates, which are useful to monitor DNA lesions and to reveal interstrand crosslinks repair defects, in particular in patients selected from Fanconi Anemia (FA) patients, xeroderma pigmentosum (XP) patients, acute myeloid leukemia (AML) patients, head-and-neck cancer patients, ovarian cancer patients and breast cancer patients.

IPC Classes  ?

• C07C 237/20 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
• A61P 7/06 - Antianaemics

Abstract

The invention pertains to new viral-like particles (VLPs), pharmaceutical compositions comprising the same and methods of using the same to prevent or treat an infection by a Coronaviridae virus. Advantageously, these VLPs can be used as a vaccine to be orally or nasally administrated.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The invention relates to the field of patient's care and describes method and systems, for prediction of mortality, functional outcome and recovery after status epilepticus, based on machine classifiers and logistic regression functions, and using biological markers and variables easily obtainable in intensive care units.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

The present results show that KDM1A is a key epigenetic regulator of tissue-specific expression of GIP receptor and possibly of other receptors from the G-protein coupled receptor family in hormone-producing glands, and that its alteration leads to the development of aberrant overexpression of eutopic hormone receptors or expression of ectopic hormone receptors that lead to abnormal steroidogenesis. They also show that loss of expression of KDM1A is likely to be the initiating event that trigger the abnormal cell proliferation leading to the development of tissue lesions in adrenal and possibly in other endocrine tissues (notably in the adrenal glands). The present invention therefore proposes to detect altered expression of KDM1A in the genome of subjects, in order to diagnose a genetic predisposition to an endocrine disease and/or to an endocrine hyperplasia. On another hand, the present results suggest that the physiological eutopic GIP receptor expression in the pancreas may be also epigenetically regulated by KDM1A. This expression could be pharmacologically targeted by KDM1A inhibitors so as to treat patients suffering from diabetes mellitus and other metabolic diseases.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a new and specific T-cell therapy strategy based on the use of memory stem T-cells (Tscm). This new cellular immunotherapy may be applied to PML patients but also to other infections or cancers for which the specific memory T cell responses are functionally impaired.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• B29C 48/00 - Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired formApparatus therefor
• B29K 25/00 - Use of polymers of vinyl-aromatic compounds as moulding material
• B29K 35/00 - Use of polymers of unsaturated polycarboxylic acids as moulding material
• B29K 201/00 - Use of cellulose, modified cellulose or cellulose derivatives, e.g. viscose, as reinforcement
• B29L 31/00 - Other particular articles
• B32B 27/30 - Layered products essentially comprising synthetic resin comprising vinyl resinLayered products essentially comprising synthetic resin comprising acrylic resin
• C08J 5/18 - Manufacture of films or sheets
• C08L 25/06 - Polystyrene
• C08L 51/04 - Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCompositions of derivatives of such polymers grafted on to rubbers

Abstract

This invention relates to the treatment of macular edema. Macular edema is the main cause of vision loss during diabetic macular edema, wet AMD (Age Related Macular Degeneration), retinal vein occlusion and chronic intraocular inflammation. Currently, beyond photocoagulation by laser irradiation, two types of drugs are used, protein molecules that neutralize VEGF family members and glucocorticoids, with different mechanisms of action, but targeting one single symptom: macular edema. The inventors have now found that macular edema may be treated by increasing the oncotic pressure of the vitreous. According to the inventors' understanding, causing an increase in the oncotic pressure of the vitreous induces a liquid flow from the interstitial water accumulated in the retina tissue to the vitreous compartment, so as to reduce or stop macular edema. Increasing the oncotic pressure of the vitreous is preferably performed by intravitreal injection of an oncotic pressure-increasing macromolecule, which macromolecule may be selected in a group comprising protein or non-protein macromolecules, such as albumin, gelatin, alpha2 macroglobulin, fibrinogen, haptoglobin multimers, beta lipoproteins and antibodies, as well as dextran and hydroxyethyl starch.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61K 38/01 - Hydrolysed proteinsDerivatives thereof
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61P 27/02 - Ophthalmic agents
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Abstract

The present invention primarily relates to a protein, in this case decorin, or a fragment thereof, for use in the treatment of an eye disease in a person in need thereof (i) the eye disease being characterised by a tear in or partial or total loss of the retinal pigment epithelium (RPE) in the person; and (ii) the protein comprising a protein sequence that comprises at least 85% sequence identity with the sequence SEQ ID NO: 1 or with the sequence SEQ ID NO: 2. The invention also relates to the implementation, for the same purpose, of a nucleic acid sequence encoding such a protein, and to the use of this protein, or a fragment thereof, or of the nucleic acid sequence to repair or regenerate a retinal pigment epithelium (RPE) in a person in need thereof.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/02 - Ophthalmic agents
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A non-invasive method for determining a characteristic length representative of a quality of collagenic organs of a patient, includes acquisition of at least one image of a cutaneous replica of a portion of the skin surface of the patient, the cutaneous replica being obtained from a skin patching device applied on the portion of the skin surface; processing of the acquired image in order to obtain a processed image, said processed image being formed by a plurality of geometrical shapes; extraction of a plurality of features from the plurality of geometrical shapes; determination of the characteristic length representative of the quality of the collagenic organs of the patient based on the extracted features.

IPC Classes  ?

• G06T 7/00 - Image analysis
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume

Abstract

A liquid pharmaceutical composition comprising an aqueous solvent, nicotinamide and at least one imipridone derivative of formula (I). A process for manufacturing said liquid pharmaceutical composition, wherein the process comprises the steps of (a) Dissolving nicotinamide in an aqueous solvent, preferably water; (b) Adding at least one pH modifier and at least one imipridone derivative to the solution obtained in step (a); and (c) Optionally sterilizing the solution obtained in step (b). A 1: 1 imipridone derivative nicotinamide complex or cocrystal, wherein the imipridone derivative is of formula (I). Said compositions for use in the treatment of cancer.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

An observational cohort with 40 patients (20 patients with primary FSGS and maladaptive FSGS, respectively) was carried out to identify renal morphometric parameters of interest. In addition, a validation cohort with 40 patients (20 patients with primary FSGS and maladaptive FSGS, respectively) was established to confirm the results matching age. estimated glomerular filtration rate (eGFR), and level of proteinuria. In the observational cohort, they found that the mean interglomerular area (MIA), a marker of glomerular scarcity described in the table 2) was significantly lower in patients with primary FSGS compared to maladaptive FSGS 90 [76-100] vs. 198 [165-299] μm2. p<0.0001. This finding was confirmed in the validation cohort 133 [109-159] vs. 204 [170-339] μm2 (p=0.0017). The present invention relates to a method for estimating the probability of maladaptive glomerular impairment in a subject comprising the following steps: i) obtaining a biological sample from said subject: ii) determining mean interglomerular area (MIA) value and iii) concluding that the subject has a high probability of maladaptive glomerular impairment when the MIA value is higher than the reference value: or concluding that the subject is not likely to have maladaptive glomerular impairment when the MIA value is lower than the reference value.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Abstract

The present invention is in the field of amyotrophic lateral sclerosis (ALS) and relates to human interleukin-2 (IL-2) for use in the treatment of amyotrophic lateral sclerosis in a human subject, wherein each dose of human IL-2 administered to said subject is between 0.1×106 to 3×106 international units (IU). Human IL-2 is preferably administered in cycles of 3 to 7 days of once-daily sub-cutaneous injection of 0.1×106 to 3×106 IU human IL-2. The treatment does not comprise the administration of regulatory T cells to the subject, who is preferably also under riluzole treatment. The administered human IL-2 is preferably not complexed with anti-hIL-2 antibodies and the treatment also preferably does not comprise the administration of rapamycin or any other suppressive agent of effector T cells (Teffs) to the subject. The treatment permits to decrease plasma CCL2 concentration and to change the polarization of blood macrophages from an M1 inflammatory phenotype to an anti-inflammatory M2 phenotype involved in tissue repair.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to a passive injection device for a catheter, having pistons in an integral assembly, at least two push bodies, and an injection body. In a first step, the removal of the integral piston assembly creates a vacuum in the push bodies, and the suction of the substance to be absorbed into the injection body. In a second step, the atmospheric pressure that is applied to the heads of the push pistons advances the integral assembly and allows the substance to be injected at a velocity proportional to the ambient pressure. The device also makes it possible to detect partial or complete obstructions in catheter lines.

IPC Classes  ?

• A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
• A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
• A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically

Abstract

The present invention relates to in vitro method for determining the likelihood of occurrence of bronchiolitis obliterans syndrome (BOS) in an individual who is a lung transplant recipient comprising at least the steps of (a) measuring the level of extracellular-vesicular (EVs)-bound HLA-G (EVs-HLA-G+) in a sample previously collected from said individual, (b) comparing the level of (EVs-HLA-G+) obtained at step (a) with a reference value; and (c) determining the likelihood of occurrence of BOS in said individual based on the comparison of step (c).

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A method for identifying, in a set of antibody targets, antibody targets corresponding to antibodies in a serum is disclosed. A set of measurement values are obtained by solid phase assays. A measurement value obtained for an antigen is representative of an amount of one or more antibodies bound to the solid phase and directed against one or more antibody targets present on the antigen. For each antigen, a subset of antibody targets present on the antigen is obtained. A search of a candidate vector associated with the lowest error is performed. A candidate vector includes a component for each antibody target in the set of possible antibody targets and a component represents a quantitative contribution to a measurement value of the corresponding antibody target. The error associated with a candidate vector is based on a sum of squared antigen errors across the set of antigens. An antigen error is obtained by comparing the sum of quantitative contributions in the candidate vector with the measurement value obtained for the concerned antigen. The antibody targets corresponding to the non-zero components in the candidate vector associated with the lowest error are identified.

IPC Classes  ?

• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to an ex vivo method for predicting peptide- receptor radionuclide therapy (PRRT) efficacy in a patient with a malignant tumor, comprising the steps of: a) Measuring the radioactivity emitted by radionuclides after a first cycle (C1) and a second cycle (C2) of PRRT to the patient, wherein C2 is performed less than 9 months after C1, and b) comparing the radioactivity at C1 and the radioactivity at C2, Wherein: - If the radioactivity at C2 is inferior to the radioactivity at C1, the complete PRRT is considered likely to have an efficacy for the patient, or - If the radioactivity at C2 is superior to the radioactivity at C1, the complete PRRT is considered unlikely to have an efficacy for the patient.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a pharmaceutical composition comprising a GLP-1R agonist such as liraglutide or semaglutide, a buffer selected from a tromethamine buffer and a phosphate buffer, and an isotonic agent selected from glucose, a polyethylene glycol and glycerol. The present invention also relates to said pharmaceutical composition for use in a method for treating joint diseases.

IPC Classes  ?

• A61K 38/26 - Glucagons
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

The invention relates to a new peptide containing a TERT epitope which presents good immunogenicity and is useful for immunotherapy of cancer.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 35/00 - Antineoplastic agents
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

The invention pertains to interleukin-1 (IL-1) and compositions comprising the same for use in the prevention and/or the treatment of an allergy, particularly in a method of desensitization. The invention also pertains to compositions comprising IL-1 with an allergen, medical devices comprising the same and kits for desensitization.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61P 37/08 - Antiallergic agents

Abstract

The present invention relates to cannabidiol (CBD), prodrugs thereof and pharmaceutically acceptable salts thereof, or a composition comprising such a compound, for use in the treatment or prevention of pain caused by an indoleamine 2,3-dioxygenase-1 (IDO1) related disease.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Abstract

The invention relates to a method for monitoring a person, the method comprising - a) recording sounds produced by the person during a recording period; - b) using a processing unit to implement a classification algorithm classifying each sound recorded during the recording period in order to classify each recorded sound into a set of classes, the set of classes comprising at least a first class of interest, representing respiratory anomalies in the person and/or a change in their manner of breathing; - c) depending on the number of sounds classified in the first class of interest, emitting a warning signal indicating a potential fall risk of the person.

IPC Classes  ?

• G08B 21/04 - Alarms for ensuring the safety of persons responsive to non-activity, e.g. of elderly persons
• G08B 31/00 - Predictive alarm systems characterised by extrapolation or other computation using updated historic data
• G08B 29/18 - Prevention or correction of operating errors

Abstract

The invention relates to an engineered glomerular endothelial cell comprising a reduction in expression of a human leukocyte antigen and its use in an in vitro method for determining the likelihood of occurrence of a non-HLA antibody mediated rejection against a renal allograft in an individual in need thereof. The inventors have observed that by suppressing expression of HLA class I and II molecules it was possible to obtain a cell able to bind non-HLA antibodies. The in vitro diagnostic method has been validated on a cohort of patients.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention relates in particular to a method for detecting a peptide biomarker in a biological fluid comprising the steps of: providing a biological fluid sample; adding the fluid to a sensor system comprising, in a 2 to 5 M solution of alkali metal halide, alkaline earth halide or mixtures thereof having a pH of between 3 and10, at least one aerolysin nanopore inserted into a lipid or polymer membrane, the fluid being added on the cis side of the membrane; applying a difference in potential of between -300 and +300 mv to the system comprising the fluid, so as to promote the passage of the at least one biomarker; recording the electrical signal generated at a frequency of 100 kHz to 1 MHz; analysing the signal, the analysis of the generated electrical signal making it possible to detect the presence and/or to determine the concentration or absence of the biomarker.

IPC Classes  ?

• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/487 - Physical analysis of biological material of liquid biological material
• G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard

Abstract

A magnetic locking device for a pipetting tool, the device having a plate that is able to be adapted to the pipetting tool, an accessory being intended to be fastened to a fastening end piece that is supported by the plate and/or intended to be supported by the pipetting tool. The device has at least one lock configured to switch from an active state to a passive state, and vice versa, such that, in the active state, the lock is able to block, in service, particles that are present in the accessory, and such that, in the passive state of the lock, the particles are free to move in the accessory.

IPC Classes  ?

• B01L 3/02 - BurettesPipettes
• G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
• G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices

Abstract

The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/45 - Transferases (2)
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 38/51 - Lyases (4)
• A61P 13/06 - Anti-spasmodics
• C12N 15/86 - Viral vectors

Abstract

The invention relates to an activation tool (3) comprising in particular: a coupling device (17) interposed between a first shaft (9) and a second shaft (15), which is configured to couple the first shaft (9) and the second shaft (15) in a first mode, referred to as the activation mode, when the first shaft (9) and the second shaft (15) exhibit the same rotational speed, and is configured to angularly decouple the first shaft (9) and the second shaft (15) in a second mode, referred to as the failure mode, when a rotational speed of the second shaft (15) is higher than the rotational speed of the first shaft (9), means (19) for detecting the switch from the first mode to the second mode. The invention relates to an activation tool (3) comprising in particular: a coupling device (17) interposed between a first shaft (9) and a second shaft (15), which is configured to couple the first shaft (9) and the second shaft (15) in a first mode, referred to as the activation mode, when the first shaft (9) and the second shaft (15) exhibit the same rotational speed, and is configured to angularly decouple the first shaft (9) and the second shaft (15) in a second mode, referred to as the failure mode, when a rotational speed of the second shaft (15) is higher than the rotational speed of the first shaft (9), means (19) for detecting the switch from the first mode to the second mode. The invention also relates to a distraction assembly (1) having an activation tool (3) of the above-mentioned type, and a plate distractor (5).

IPC Classes  ?

• A61B 17/66 - Compression or distraction mechanisms
• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
• A61B 17/68 - Internal fixation devices

Abstract

The present invention relates to a combination product comprising an antibiotic and at least one non-pathogenic microorganism for simultaneous, separate, or sequential use in preventing emergence of resistance to the antibiotic when treating a colonization and/or an infection caused by a bacterium that is susceptible to said antibiotic, wherein said at least one non-pathogenic microorganism is resistant to said antibiotic.

IPC Classes  ?

• A61K 31/74 - Synthetic polymeric materials
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/665 - Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
• A61P 31/04 - Antibacterial agents

Abstract

A method for generating a 3D anatomical models using segmented images representing anatomical structures and 3D representation of fibers is disclosed. The method comprises obtaining an input image of said anatomical region of interest and a 3D representation of fibers in an anatomical region of interest; performing a segmentation of the input image to generate a first, second and third segmented images by detecting voxels that represent respectively a bone, an organ or a vessel and using respectively a first, second and third segmentation neural network applied to the input image; performing a segmentation of the input image to generate a fourth segmented image by detecting voxels that represent a bone, an organ or a vessel using a fourth segmentation neural network; generating an aggregated segmented image by combining the segmented images; performing a nerve detection in a 3D representation of fibers in an anatomical region of interest using a nerve definition and transforming the said nerve definition into 3D fuzzy search space composed by one or more 3D fuzzy areas. The 3D anatomical model is generated using the aggregated segmented image and the detected fibers representing the nerves.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation

Abstract

The present invention relates to the prevention and/or treatment of metabolic diseases such as overweight and obesity as well as complications related thereto. The present invention more specifically relates to the bacterium Turicimonas muris or fragments thereof for preventing and/or treating metabolic diseases and complications related thereto.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 35/741 - Probiotics
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/365 - Lactones
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• A61Q 19/06 - Preparations for care of the skin for countering cellulitis
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 38/26 - Glucagons
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 31/64 - Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to the prevention and/or treatment of metabolic diseases, such as overweight and obesity, and complications related thereto. The present invention more specifically relates to the bacterium Turicimonas muris or fragments thereof for preventing and/or treating metabolic diseases and complications related thereto.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 35/741 - Probiotics
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/365 - Lactones
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• A61Q 19/06 - Preparations for care of the skin for countering cellulitis

Abstract

Faecalibacterium prausnitziiClostridioides difficileClostridioides difficile infection in an individual.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61P 31/04 - Antibacterial agents
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention relates to a tube (1) for the enteral feeding of premature newborn babies comprising: - a first lumen (2) having a proximal end (2a) and a distal end (2b) to be housed in the digestive tract, - a second lumen (3) having a proximal end (3a) and a distal end (3b) protruding from the distal end (3b) of this lumen (3), - an inflatable/deflatable balloon (5), the balloon (5) being positioned around a portion of the distal end (2b), the tube (1) comprising a third lumen (4) having a distal end (4b) connected to the balloon (5) and a proximal end (4a) that can be connected to inflation/deflation means, - the tube (1) being able to be inserted into the digestive tract, the distal end (2b) being housed in the stomach, the inflated balloon (5) being able to be positioned in abutment against the cardia, so as to close the stomach, the distal end (3b) of the second lumen (3) being positioned in the oesophagus before the cardia.

IPC Classes  ?

• A61J 15/00 - Feeding-tubes for therapeutic purposes

Abstract

A tool for generating a plasma, the tool having at least one instrument, the instrument having at least a power supply electrode, an internal dielectric screen, a counter electrode, and a sheath. A device that has such a tool.

IPC Classes  ?

• A61N 1/44 - Applying ionised fluids

Abstract

The present invention is directed to methods of diagnosis and treatment of autoimmune, chronic inflammatory and lymphoproliferative diseases based on the identification of a population of pathogenic B and/or T cells showing a specific phenotype. These cells may be identified by their specific pattern of expression of marker proteins.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to the field of anticancer treatment, more specifically to methods for ex vivo determining whether a patient with hematological malignancies is likely to benefit from allogeneic hematopoietic stem cell transplantation (allo-HSCT) by analyzing the gut microbiota in a fecal sample from said patient; the present invention also relates to treatments aimed to reduce the risk of relapse following allo-HSCT.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A61P 31/04 - Antibacterial agents
• A61K 35/74 - Bacteria
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present disclosure concerns a Reg3α polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for protecting oxygen sensitive gram-positive bacteria, compositions including the polypeptide, and their use. The disclosure shows that increasing concentration of the hReg3α lectin into the gastrointestinal tract (GIT) lumen of hReg3α-transgenic mice induced significant changes in composition of gut microbiota, and dramatically improved host resistance to intestinal inflammation. The Reg3α polypeptide may be used for preventing or treating microbiota-related diseases and/or disorders, including inflammatory bowel disease (IBD), colitis, gastrointestinal infections, irritable bowel syndrome and other gastrointestinal functional diseases, gastrointestinal tract cancer, metabolic syndrome and obesity, diabetes, liver diseases, allergic diseases, neurodegenerative diseases and psychological disorders, and the prevention and treatment methods may also include transferring to said patient fecal microbiota from a human or animal expressing the Reg3α polypeptide.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A23L 33/19 - Dairy proteins

Abstract

The invention relates to a method for characterizing the vibration of a surface of the chest of an individual, said method including generating an incident vibration of the respiratory system of the individual, said incident vibration having at least one frequency from 20 Hz to 5000 Hz, to obtain resultant vibrations at a surface S of the chest of the individual, said surface S having a surface area of at least 10 cm2 and being characterized by a plurality of points Pi, and measuring the oscillation of each point Pi using a measuring device and obtaining the signal Spi of the resultant vibration at each of the points Pi, said measuring device being arranged at a distance from the chest of said individual, and characterizing each signal Spi at the frequenc(y/ies) of the signal Spr.

IPC Classes  ?

• A61B 5/08 - Measuring devices for evaluating the respiratory organs
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The invention relates to a novel epitope of PTPRZ1 which presents good immunogenicity and is useful for immunotherapy of cancer.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

The present invention relates to a compound selected from dyclonine, a dyclonine analog and a pharmaceutically acceptable salt thereof, or a composition comprising such a compound, for use in the topical treatment and prevention of hand-foot syndrome.

IPC Classes  ?

• A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 17/00 - Drugs for dermatological disorders

Abstract

The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.

IPC Classes  ?

• A61K 39/35 - Allergens
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/70 - Web, sheet or filament bases
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/36 - Allergens from pollen

Abstract

T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sezary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors studied the regulatory T phenotype of Sezary cells and showed the expression of CCR8 (CD198) by Sezary cells and other T-cell lymphoma cell lines. CCR8 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CCR8-expressing cancer cells would eliminate tumor cells and also activate the anti-tumor immunity in T-cell lymphomas.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Limosilactobacillus mucosae Limosilactobacillus mucosae , or a lysate or culture supernatant thereof, for use in the prevention and/or treatment of disorders requiring an increase in GLP-1 production in a subject in need of GLP-1, the disorders being selected from (i) a disorder related to dysregulation of insulin sensitivity and/or blood glucose concentration and (ii) loss of muscle mass and/or muscle function.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• C12R 1/01 - Bacteria or actinomycetales
• C12R 1/225 - Lactobacillus
• C12R 1/23 - Lactobacillus acidophilus
• C12R 1/245 - Lactobacillus casei
• C12R 1/46 - Streptococcus
• C12R 1/85 - Saccharomyces
• C12R 1/865 - Saccharomyces cerevisiae

Abstract

The invention relates to a method for detecting an insufficient quantity of liquid in a reservoir (11) of a nebuliser (10), the nebuliser being configured to form an aerosol from the liquid present in the reservoir, so as to deliver an active principle, present in the aerosol, to a user, the method comprising: - a) detecting, by a microphone (2), a sound produced, at different times, by the aerosol formation; - b) processing, at each time, the detected sound by means of a processing unit (3), so as to extract therefrom at least one characteristic of the sound; - c) depending on each characteristic extracted during step b), detecting, by means of the processing unit, an insufficient quantity of liquid in the reservoir for the delivery of the active principle.

IPC Classes  ?

• A61M 11/06 - Sprayers or atomisers specially adapted for therapeutic purposes of the injector type

Abstract

The present invention relates to the prognosis and diagnosis of upcoming birth. More specifically, the invention relates to a new combination of biomarkers for upcoming birth that enables the accurate prognosis and diagnosis of upcoming delivery, and in particular enables the accurate prognosis and diagnosis of preterm delivery.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention provides compounds able to induce neuroprotection of damaged neurons and boost the remyelination potential of oligodendrocytes. The compounds have been identified through methods of pharmacological screening of a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Disclosed is a device for the perfusion of an organ, including: a container of fluid, containing an organ bathed in the perfusion fluid; a first path including an inlet, an outlet and a pump; and a second path including an inlet, an outlet and a pump. The “arterial” outlet of the first path has a diameter smaller than a diameter of the “portal” outlet of the second path. The device additionally includes, between the pump and the outlet of the first path and/or between the pump and the outlet of the second path, an oxygenation unit arranged to oxygenate the fluid emerging from the “arterial” outlet of the first path more than the fluid emerging from the “portal” outlet of the second path. The device can include a communication path between the first path and the second path in order to oxygenate the second path. Use in liver transplantation.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts

Abstract

The invention relates to MnTBAP or Mn(III) substituted pyridylporphyrin (MnP) compounds selected among MnTE-2-pYP5+, MnTEHex-2-Pyp5+ and MnTnBuOE-2-Pyp5+ for use in treating sepsis and/or reversing sepsis-induced microglial cells alteration(s), and/or reversing associated long-term cognitive impairment in a subject diagnosed with sepsis or sepsis-associated encephalopathy (SAE), and/or treating long-term cognitive impairment in a subject suffering from sepsis or sepsis-associated encephalopathy (SAE).

IPC Classes  ?

• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

An organ perfusion and preservation system for use in preserving an organ from a donor, may include a fluid reservoir, a heat exchanger in fluid communication with the fluid reservoir and configured to selectively raise and lower a temperature of a perfusion fluid, an oxygenator configured to oxygenate the perfusion fluid, an inflow pump in fluid communication with the fluid reservoir and the oxygenator, a fluid inflow line configured to transport perfusion fluid from the oxygenator to the organ, a fluid outflow line configured to transport perfusion fluid away from the organ and back to the reservoir, an outflow pump in fluid communication with the fluid outflow line and the fluid reservoir, and a controller operatively connected to the inflow pump, the outflow pump, and the heat exchanger, wherein the controller is configured to select parameters to reversibly heat and reversibly cool the organ.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts

Abstract

The present disclosure provides methods for generating and/or purifying secretomes, extracellular vesicles, and fractions thereof, from progenitor cells; and provides compositions containing such generated secretomes, extracellular vesicles, and fractions thereof. The present disclosure further provides methods for analyzing activities, and the functionality and potency, of such secretomes, extracellular vesicles, and fractions thereof. The present disclosure also relates to the therapeutic use of secretomes, extracellular vesicles, and fractions thereof. The present disclosure further relates to good manufacturing practices (GMP)-ready, scalable, culture protocol for the release of clinic-ready secretomes.

IPC Classes  ?

• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
• A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 5/074 - Adult stem cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• B01D 21/26 - Separation of sediment aided by centrifugal force
• B01D 37/00 - Processes of filtration
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus

Abstract

The invention relates to a method for hepatocellular carcinoma (HCC) risk stratification in patients, in particular with advanced chronic liver disease or cirrhosis using combinations of single nucleotide polymorphisms (SNPs), alone or with blood markers.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors have set up candidate vaccines against Chlamydia trachomatis. In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to in silico analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope). Finally, the inventors have generated some specific CD40 or Langerin antibodies comprising one or more identified epitope(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to Chlamydia trachomatis (Ct) antigenic polypeptides and uses thereof for vaccine purposes.

IPC Classes  ?

• C07K 14/295 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Chlamydiales (O)
• A61K 39/118 - Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

It is disclosed a computer-implemented method for processing radiological brain images of a patient with ischemic stroke, wherein the radiological brain images comprise either brain Magnetic Resonance Images comprising at least diffusion- weighted imaging DWI and a perfusion weighted imaging PWI, or brain Computed tomography images, comprising at least a non-contrast acquisition and a perfusion imaging acquisition, the method comprising: determining, based either on MRI-DWI or CT images, and an atlas of brain regions of high eloquence, an amount of ischemic core lesions within high eloquence regions, determining, based either on MRI-PWI or CT images, and the atlas of brain regions of high eloquence, an amount of hypoperfused lesions within high eloquence regions, - Computing a ratio between the amount of hypoperfused high-eloquence regions and the amount of ischemic core lesions within high eloquence regions.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation

Abstract

The present invention relates to methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof. In particular, the present invention relates to a method for performing antisense oligonucleotide-mediated exon skipping in a retina cell of a subject comprising the step of injecting into the vitreous of the subject an amount of the antisense oligonucleotide.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to a method for ultrasound imaging of a microvascular structure, which method characterised in that it comprises: - a step of injecting ultrasound contrast agents into blood vessels in a region comprising a microvascular structure, - a step of ultrasound imaging the region comprising the microvascular structure while the contrast agents flow through the blood vessels, the concentration of the contrast agents and/or the ultrasound frequency of the imaging being chosen such that the contrast agents are sufficiently separated to prevent feedback, - a step of detecting/filtering and locating the contrast agents, - a step of individually monitoring the contrast agents, - a step of classifying the behaviours of the individually monitored contrast agents according to at least one predetermined behaviour characteristic of contrast agents flowing through the microvascular structure, and - a step of imaging the microvascular structure according to the thus-performed classification.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• A61B 8/06 - Measuring blood flow

Abstract

The present invention relates to a kit and an in vitro method for detecting and characterizing the degradation of a particular organ or tissue, on the basis of the analysis of the presence of at least one specific methylated cell-free DNA in a biological sample. More particularly, the invention relates to a kit and a method for detecting and characterizing the degradation of an organ selected from: the brain, the lung and the kidney, and/or of a tissue present in this organ. The invention also relates to a method for the in vitro diagnosis of a disease or condition involving the lysis of an organ or tissue.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Glycosylphosphatidylinositol (GPI) is a glycolipid that anchors more than 150 proteins to the cell surface. Pathogenic variants in several genes that participate in GPI biosynthesis cause inherited GPI deficiency (IGD) disorders. Here, the inventors reported that homozygous null alleles of PIGG, a gene involved in GPI modification, are responsible for the rare Emm-negative blood phenotype. Using a panel of K562 cells defective in both the GPI-transamidase and GPI remodeling pathways, they demonstrate that the Emm antigen, whose molecular basis has remained unknown for decades, is carried only by free GPI and that its epitope is composed of the second and third ethanolamine of the GPI backbone. Importantly, the inventors show that the decrease in Emm expression in several IGD patients is indicative of GPI defects. Overall, our findings establish Emm as a novel blood group system and have important implications for understanding the biological function of human free GPI.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types

Abstract

A method for detecting an anomaly in the wearing of a respiratory mask fitted to the face of a user, comprising: - a) detection, by a microphone, of a sound produced, at different instants, by an expiration or inspiration of the user through the mask; - b) processing of the detected sound, by a processing unit, at each instant so as to extract therefrom at least one characteristic of the sound; - c) as a function of each characteristic extracted during step b), detection, by the processing unit, of an occurrence of an anomaly in the wearing of the mask.

IPC Classes  ?

• A61M 16/06 - Respiratory or anaesthetic masks

Abstract

The invention relates to the use of IL-2 in treating autism spectrum disorder (ASD) in a subject, as well as in preventing ASD in children, by administering the IL-2 to a child at risk of ASD or to a pregnant mother at risk of having a child with ASD.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

System (1) for predicting an at least partial rupture or the detachment of a vascular plaque which could lead to a stroke or for analysing the biomechanical properties of the wall of an internal jugular vein in order to predict a risk of thrombosis, comprising: a monitoring device (2) comprising a temperature sensor (5) configured to measure the temperature of the vascular plaque or the wall of the jugular vein, a vibration sensor (4) configured to measure mechanical waves passing through the vascular plaque and the underlying walls, a motion sensor (6) configured to measure the movements of the plaque or the wall of the jugular vein (6), an electrical sensor configured to measure a parameter related to the electrical impedance of the plaque, an acoustic wave sensor and a calculation unit (10) configured to analyse the data from the monitoring device (2) by artificial intelligence.

IPC Classes  ?

• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/053 - Measuring electrical impedance or conductance of a portion of the body

Abstract

The invention relates to an in vitro method for detecting or monitoring an endometrial or ovarian carcinoma in a human subject, which method comprises detecting, or determining the level of, methylation of OXT and/or ZSCAN12 gene in a biological sample from the subject.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The inventors explored in an allogeneic situation the regulatory potential of Mucosal-Associated Invariant T cells (MAIT cells), a population of unconventional T cells that exhibit potent antibacterial activity, expressing a semi-invariant TCR which recognizes vitamin B2 derivatives of microbial origin presented by the MR1 molecule. In particular, the inventors used i) an allogenic reaction model in vitro (mixed lymphocyte reaction, MLR) and ii) murine model of xenogeneic aGvHD They first verified that human MAIT cells do not proliferate in response to allogeneic stimulation in vitro (MLR) or in vivo (immunodeficient mice) alone but require for their expansion both an inflammatory environment and TCR ligation by its ligand. In contrast, MAIT cells are able to inhibit the proliferation of allospecific LT in vitro in a dose-dependent manner. Furthermore, the adoptive transfer of MAIT cells in a mouse model of xeno-GVHD resulted in a delay in early or late GvHD development. Altogether, these data describe a new regulatory function of MAIT cells in an allogeneic context, allowing us to consider their use in cell therapy to limit GvHD.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The invention relates to an in vitro method of determining whether a human patient has lesions rendering said patient at risk of a gastric cancer condition and/or needs further medical test in relation thereto, comprising screening a biological sample of blood or plasma, where the level of at least two biomarkers selected amongst: PGK1, CFP, IGFALS, KRT19, SPRR1A, CPA4, CA2, SERPINA5, MAN2A1, KIF20B, SPEN, JUP, KRT6C, CDSN, KPRP, F13A1, SAA1 (SAA2), LBP, DSP, KRT2, KRT14, ARG1, S100A12, ATAD3B, MAN1A1, HAL, DCD, 07, HP, LEP, IL-8, IL-17, TNF-alpha, USF1, USF2, SELE, MSLN, EGFR, STATS and mtDNA level is determined, with the proviso that the selected biomarkers do not consist of the association of IL-8 and mtDNA level. The method may be for assessing the risk that a human patient has a non-atrophic gastritis (NAG), or an atrophic gastritis/pre-neoplasia (AG/P), or a gastric cancer (GO), or for discriminating between those risks or presence of these conditions. In a particular aspect, the method may comprise as a distinct, simultaneous or parallel step, a step of detecting an Helicobacter pylori infection. The invention also relates to a kit suitable for carrying out such a method, or a set of markers, and the use of the same for determining whether a human patient has lesions rendering said patient at risk of a gastric cancer condition and/or needs further medical test in relation thereto, or for prognosing or diagnosing a gastric pre-cancer condition or a gastric cancer condition.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention relates to an embolizing emulsion comprising iodinated oil and an aqueous phase comprising a water-soluble contrast agent for use in the treatment of inflammatory hypervascularization associated with a musculoskeletal disorder.

IPC Classes  ?

• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 33/18 - IodineCompounds thereof
• A61K 36/66 - Papaveraceae (Poppy family), e.g. bloodroot
• A61K 9/107 - Emulsions

Abstract

The present invention relates to an immunogenic composition comprising at least one Staphylococcus aureus antigen, wherein said antigen is a polypeptide having at least 80% identity with the SdrH-like polypeptide of SEQ ID NO: 8, Nuc of SEQ ID The present invention relates to an immunogenic composition comprising at least one Staphylococcus aureus antigen, wherein said antigen is a polypeptide having at least 80% identity with the SdrH-like polypeptide of SEQ ID NO: 8, Nuc of SEQ ID NO: 4, or LukG of SEQ ID NO: 12, an immunotherapeutic composition comprising a polyclonal antibody which selectively binds to at least one of said antigens, and an in vitro method of identifying an antigen conferring protection against disease caused by S. aureus in a subject.

IPC Classes  ?

• A61K 39/085 - Staphylococcus
• A61K 39/40 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum bacterial
• A61P 31/04 - Antibacterial agents
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12Q 1/18 - Testing for antimicrobial activity of a material

Abstract

The invention relates to a method for detecting polyps from a video sequence comprising a plurality of images, said method comprising, after an extraction of regions of interests likely to contain a polyp within the different images, a description of said regions and a classification of said regions as likely to contain a polyp or not, the following steps: an aggregation of same regions of interest on said images called first aggregation, said first aggregation consisting of maintaining as a region of interest belonging to the first class on a given image, a region of interest also classified in the first class for each successive images; then: an aggregation of images called second aggregation, said second aggregation consisting of maintaining as a region of interest on any image comprised between a first image and a second image, a region of interest appearing for the first time on said first image and for the last time on said second image.

IPC Classes  ?

• G06F 18/243 - Classification techniques relating to the number of classes
• G06V 20/40 - ScenesScene-specific elements in video content
• G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
• G06V 10/62 - Extraction of image or video features relating to a temporal dimension, e.g. time-based feature extractionPattern tracking

IPC Classes  ?

• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations

Abstract

The present invention allows a rapid and early diagnosis of bacterial or viral infection. Such a diagnosis is highly desired among patients admitted in emergency department to allow the initiation of the appropriate treatment. Although no biomarker alone can offer an appropriate diagnosis with sufficient sensitivity and specificity, the present invention defines optimal combinations of biomarkers allowing the diagnosis of infection.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to a system (1) for providing a method for the automated analysis of cardiotocographic data (CTO), in order to measure the risk of fetal hypoxia (RSK), of between 0% for absence of any risk and 100% for confirmed fetal hypoxia. The system (1) according to the invention makes it possible, by means of the artificial intelligence model (IA) facilitated by the neural network (23) and by means of the mathematical regression model, to determine the contributions (CTR) of the various risk indicators (IND) capable of being subsequently interpreted by practitioners. The models for assessing the risk of fetal hypoxia (RSK), determined by means of a neural network (23), and the contributions (CTR) of the various indicators (IND) used to determine the risk of fetal hypoxia (RSK), determined by logistic regression (24), are trained on a retrospective database.

IPC Classes  ?

• A61B 5/288 - Invasive for foetal cardiography, e.g. scalp electrodes
• A61B 5/344 - Foetal cardiography
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The invention relates to a method for training a model for predicting occurrence of an epileptic seizure, the method comprising performing a supervised training over a training dataset of a nonlinear binary classification model configured to receive as input the evaluation, by a patient, of the intensity of each prodromal symptom among a predefined set of prodromal symptoms, and to output a classification of said patient belonging either to a pre-ictal or inter-ictal state, and the training dataset comprises data inputs obtained from a plurality of epileptic patients, each data input comprising an evaluation, by a patient, of the intensity of each of the predefined set of prodromal symptoms, each data input being further associated to an indication of said patient belonging to a pre-ictal or inter-ictal state at the time of the evaluation. The invention also relates to a prediction model obtained accordingly, and a computing device for implementing said prediction model.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The spleen clears rigid erythrocytes from the circulation. Drug-induced stiffening of Plasmodium falciparum intra-erythrocytic sexual stages (mature gametocytes) is therefore expected to block the transmission of malaria By screening 13 555 compounds with spleen-mimetic microfilters, the inventors identified 82 compounds that stiffen mature gametocytes. Eight active families were identified, including known anti-malarial, antimicrobial or anticancer agents, amongst others. Hit prioritization based on accessible safety and pharmacokinetics data in humans identified 3 leading candidates. NITD609 displayed killing and stiffening effects (IC50 of 100 and 50 nM, respectively), while TD-6450 and L-THP had a pure or predominant stiffening effect (IC50 of 600 and 5 nM, respectively). These values are lower than or close to peak plasma concentrations in humans. Clinical trials with these strong malaria transmission-blocking candidates are envisioned.

IPC Classes  ?

• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 33/06 - Antimalarials

Abstract

Congenital aniridia is a rare and severe genetic panocular disease characterized by a complete or partial iris defect clinically detectable at birth. The most common form of aniridia occurring in around 90% cases is caused by PAX6 haploinsufficiency. Ataluren eye-drops aim to restore ocular surface PAX6 haploinsufficiency in Aniridia Related Keratopathy (ARK). However, they are currently no ophthalmic solution available forms. The objective of this study was to assess the physicochemical and microbiological stability of ataluren eye-drop 1% in preservative-free low-density polyethylene (LDPE) bottle with an innovative insert that maintains sterility after opening. Because ataluren is a strongly lipophilic compound, the formulation is complex and involves a strategy based on co-solvents in an aqueous phase or an oily formulation capable of totally dissolving the active ingredient. Throughout the 60 days period, the new formulation of the solution in LDPE bottle remained clear without any precipitation or color modification, no drug loss and no microbial development were detected. Thus, the present invention refers to a pharmaceutical solution comprising: ataluren or any one of its pharmaceutically acceptable derivatives, at least one solvent selected from the group consisting in dimethylsulfoxyde (DMSO), polyethylene glycol, polysorbate, glycerol, tyloxapol, and poloxamer, and castor oil; and its use for treating aniridia.

IPC Classes  ?

• A61K 31/4245 - Oxadiazoles
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions

Abstract

The present invention relates to Lichen planus (LP), and more specifically to no erosive form of LP (NELP). The invention provides an immune signature for LP, which is not found in other cutaneomucosal chronic inflammatory diseases. The invention moreover provides different diagnosis methods and methods of treating NELP, based on this immune signature. The inventors have indeed demonstrated the presence of HPV16-specific activated CTL in blood and lesion samples corresponding to the different clinical forms of LP, not only in erosive oral LP, while a different scenario operates in other cutaneomucosal chronic inflammatory diseases. This HPV16-specific activated CTL is characterized by TCRVβ3+ CD8+ T-cells oligoclonal expansions.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention relates to an anastomosis system comprising: - a first tube (10) having a lateral surface (11), and upstream opening (13) and a downstream opening (14); - at least a second tube (100) extending from the lateral surface (11) of the first tube (10) as far as an inlet (101) of the second tube (100) and communicating with the first tube (10); - a valve (130) mounted in the second tube (100); and - a ligature device (150) arranged on the circumference of the first tube (10) downstream of the region of communication between the first tube and the second tube (120), the ligature device (150) adopting a first arrangement or a second arrangement, the first arrangement closing the first tube (10) and the second arrangement leaving said first tube (10) open.

IPC Classes  ?

• A61F 2/06 - Blood vessels